In a healthy situation, commensal bacteria maintain a symbiotic relationship with the host and modulate a proper functioning of the immune system. Maintaining intestinal microbial homeostasis has been shown to prevent occurrence of IBD. In case of disturbances, microbial management therapies such as probiotics are an effective way to modulate the gut microbiota. The potential beneficial effects of probiotics have been thought to include inhibition of invasion of pathogenic bacteria, improvement the epithelial barrier function and immunomodulation. 
Many studies have been performed on the role probiotics can play in managing IBD, however, not always with consistent findings . The diverse results can be explained by differences in dose, duration, strain-specific effects of probiotics, or personal microbial composition. Despite the contradicting study outcomes, the clear association between gut dysbiosis and IBD and lack of safe and sustainable treatment options, microbial therapies are a promising and becoming a more common approach to manage IBD. Selecting the right combination of probiotic strains that target the microbial disturbances underlying the disease, understanding how a patient’s gut microbiota respond to the intervention, and how QoL is improved in the end, has become very important in this.